GVHD incidence in the 2 groups
| . | Cs-A Dose . | P Value . | |
|---|---|---|---|
| 1 mg/kg/d . | 3 mg/kg/d . | ||
| Cs-A1 group . | Cs-A3 group . | ||
| Acute GVHD (59 evaluable patients) | |||
| Number of patients | 30 | 29 | |
| Absent | 4 (13.3%) | 6 (20.7%) | |
| Grade I | 9 (30%) | 12 (41.4%) | |
| Grade II | 9 (30%) | 7 (24.1%) | NS |
| Grade III | 4 (13.3%) | 2 (6.9%) | |
| Grade IV | 4 (13.3%) | 2 (6.9%) | |
| Organ involvement in acute GVHD (49 patients) | |||
| Number of patients | 26 | 23 | |
| Skin | 10 (38.5%) | 13 (56.5%) | NS |
| Intestine | 1 (4.3%) | NS | |
| Skin + intestine | 5 (19.2%) | 4 (17.4%) | NS |
| Skin + liver | 1 (3.8%) | 2 (8.7%) | NS |
| Intestine + liver | 1 (4.3%) | NS | |
| Skin + intestine + liver | 10 (38.5%) | 2 (8.7%) | .016 |
| Chronic GVHD (53 evaluable patients) | |||
| Number of patients | 27 | 26 | |
| Absent | 19 (70.4%) | 20 (76.9%) | |
| Limited | 6 (22.2%) | 5 (19.2%) | NS |
| Extensive | 2 (7.4%) | 1 (3.9%) | |
| . | Cs-A Dose . | P Value . | |
|---|---|---|---|
| 1 mg/kg/d . | 3 mg/kg/d . | ||
| Cs-A1 group . | Cs-A3 group . | ||
| Acute GVHD (59 evaluable patients) | |||
| Number of patients | 30 | 29 | |
| Absent | 4 (13.3%) | 6 (20.7%) | |
| Grade I | 9 (30%) | 12 (41.4%) | |
| Grade II | 9 (30%) | 7 (24.1%) | NS |
| Grade III | 4 (13.3%) | 2 (6.9%) | |
| Grade IV | 4 (13.3%) | 2 (6.9%) | |
| Organ involvement in acute GVHD (49 patients) | |||
| Number of patients | 26 | 23 | |
| Skin | 10 (38.5%) | 13 (56.5%) | NS |
| Intestine | 1 (4.3%) | NS | |
| Skin + intestine | 5 (19.2%) | 4 (17.4%) | NS |
| Skin + liver | 1 (3.8%) | 2 (8.7%) | NS |
| Intestine + liver | 1 (4.3%) | NS | |
| Skin + intestine + liver | 10 (38.5%) | 2 (8.7%) | .016 |
| Chronic GVHD (53 evaluable patients) | |||
| Number of patients | 27 | 26 | |
| Absent | 19 (70.4%) | 20 (76.9%) | |
| Limited | 6 (22.2%) | 5 (19.2%) | NS |
| Extensive | 2 (7.4%) | 1 (3.9%) | |